Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections

Ila M. Saunders; Amit Lahoti; Roy F. Chemaly; Cynthia Trevino; Michael Westmoreland; Chitra Hosing

doi:10.1177/1078155214560921

Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections

Ila M. Saunders, Amit Lahoti, Roy F. Chemaly, Cynthia Trevino, Michael Westmoreland, Chitra Hosing

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Cidofovir, a nucleoside analog of deoxycytidine monophosphate, is a water-soluble polar molecule that exhibits antiviral activity against a broad range of DNA viruses. Cidofovir for injection is approved for the treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. The safety and efficacy of topical cidofovir has been described in a limited number of patients. We present two cases of multidrug-resistant herpes simplex virus infections that responded to topical cidofovir therapy yet resulted in irreversible acute kidney injury.

Original language	English (US)
Pages (from-to)	325-331
Number of pages	7
Journal	Journal of Oncology Pharmacy Practice
Volume	22
Issue number	2
DOIs	https://doi.org/10.1177/1078155214560921
State	Published - Apr 1 2016

Keywords

Topical cidofovir
acute kidney injury
herpes simplex virus
immmunocompromised

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1177/1078155214560921

Cite this

@article{9bbfea8439794d2dbe6b0c8e2182ae9c,

title = "Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections",

abstract = "Cidofovir, a nucleoside analog of deoxycytidine monophosphate, is a water-soluble polar molecule that exhibits antiviral activity against a broad range of DNA viruses. Cidofovir for injection is approved for the treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. The safety and efficacy of topical cidofovir has been described in a limited number of patients. We present two cases of multidrug-resistant herpes simplex virus infections that responded to topical cidofovir therapy yet resulted in irreversible acute kidney injury.",

keywords = "Topical cidofovir, acute kidney injury, herpes simplex virus, immmunocompromised",

author = "Saunders, {Ila M.} and Amit Lahoti and Chemaly, {Roy F.} and Cynthia Trevino and Michael Westmoreland and Chitra Hosing",

note = "Publisher Copyright: {\textcopyright} SAGE Publications.",

year = "2016",

month = apr,

day = "1",

doi = "10.1177/1078155214560921",

language = "English (US)",

volume = "22",

pages = "325--331",

journal = "Journal of Oncology Pharmacy Practice",

issn = "1078-1552",

publisher = "SAGE Publications Ltd",

number = "2",

}

TY - JOUR

T1 - Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections

AU - Saunders, Ila M.

AU - Lahoti, Amit

AU - Chemaly, Roy F.

AU - Trevino, Cynthia

AU - Westmoreland, Michael

AU - Hosing, Chitra

N1 - Publisher Copyright: © SAGE Publications.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Cidofovir, a nucleoside analog of deoxycytidine monophosphate, is a water-soluble polar molecule that exhibits antiviral activity against a broad range of DNA viruses. Cidofovir for injection is approved for the treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. The safety and efficacy of topical cidofovir has been described in a limited number of patients. We present two cases of multidrug-resistant herpes simplex virus infections that responded to topical cidofovir therapy yet resulted in irreversible acute kidney injury.

AB - Cidofovir, a nucleoside analog of deoxycytidine monophosphate, is a water-soluble polar molecule that exhibits antiviral activity against a broad range of DNA viruses. Cidofovir for injection is approved for the treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. The safety and efficacy of topical cidofovir has been described in a limited number of patients. We present two cases of multidrug-resistant herpes simplex virus infections that responded to topical cidofovir therapy yet resulted in irreversible acute kidney injury.

KW - Topical cidofovir

KW - acute kidney injury

KW - herpes simplex virus

KW - immmunocompromised

UR - http://www.scopus.com/inward/record.url?scp=84959268592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959268592&partnerID=8YFLogxK

U2 - 10.1177/1078155214560921

DO - 10.1177/1078155214560921

M3 - Article

C2 - 25488905

AN - SCOPUS:84959268592

SN - 1078-1552

VL - 22

SP - 325

EP - 331

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

IS - 2

ER -

Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this